trending Market Intelligence /marketintelligence/en/news-insights/trending/0x2yhelnmjcjgp4f1ptl-a2 content esgSubNav
In This List

GlaxoSmithKline CEO receives £4.9M total pay for 2017

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


GlaxoSmithKline CEO receives £4.9M total pay for 2017

GlaxoSmithKline plc CEO Emma Walmsley received about £4.9 million total remuneration in 2017.

Walmsley received about £3.5 million in performance-based pay, in addition to the £1.4 million fixed pay the company granted.

In comparison, former GlaxoSmithKline CEO Andrew Witty's total remuneration in 2016 was about £6.8 million.

Walmsley has been CEO of the U.K.-based drugmaker since March 31, 2017.

The company said it will disclose the pay ratio between CEO and the average of its U.K. employees when the method for computing the ratio is finalized in new regulations.